Kyowa Hakko Released Mid-Term Business Plan For 2008-2010
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko released its mid-term business plan for fiscal years 2008-2010. Based on the integration of Kyowa Hakko and Kirin Pharma, the plan estimates net sales to reach ¥513 billion, with ¥73 billion in income before goodwill amortization and a 30+ percent dividend payout ratio by 2010. To maintain top class biopharma production, Kyowa Hakko plans to build a new antibody drug production facility inside its bio technology institute in Takasaki, Gunma Prefecture. The company also plans to build a new research facility inside the Tokyo Research Park. Total capital investment will be ¥83 billion. On the same day, Kyowa Hakko reported results for the past fiscal year ending March 31, with both sales (¥392 billion) and net income (¥23.4 billion) the highest in the company's history. (Click here for more - Japanese language